It started in 2022, when the FDA placed the active ingredients in EliLilly’s Mounjaro and Zepbound, and Novo’s Ozempic and Wegovy, on its shortage list, a designation that opened the door for ...
One of the highlights of EliLilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...
To paraphrase a Shakespeare quote, bad news and misfortune tend to come in groups. But that may also apply to good news. Just ask EliLilly (NYSE: LLY), a pharmaceutical company that has been ...